Clinical Trials Logo

Clinical Trial Summary

The research protocol aims to compare the utility of contrast enhanced abdominal sonography with computerized tomography in the evaluation of children with blunt abdominal trauma. Hemodynamically stable children ages 7-18 who are transferred to Children's Hospital on the trauma service with a CT scan of abdomen & pelvis already performed at the referring institution will be identified by the trauma service as eligible for inclusion.

The ultrasounds will be performed by one of two Attending Radiologists involved in the study. The contrast being used for the study is Optison (GE Healthcare Inc, Princeton, NJ), which is an injectable suspension of Perflutren Protein-Type A Microspheres. This has been used in echocardiography as well as abdominal ultrasonography for evaluation of pediatric abdominal and pelvic solid tumors. The contrast enhanced ultrasound will be performed by radiologist. Contrast enhancement only lasts for 3-5 minutes per injection, therefore Optison will be redosed up to 2 additional doses for the completion of the ultrasound. Vital signs will be monitored for 30 minutes after the contrast agent is given and any adverse reactions will be recorded. Adverse reactions to Optison have occurred within this time frame in the literature. Subsequent medical care will be as indicated per the clinical practice guideline.


Clinical Trial Description

Contrast enhanced ultrasound has been used clinically in Europe for the past 10 years as an evaulation tool for examining abdominal injuries in trauma among children and adults. This is a valuable diagnostic modality that could potentially reduce the need for radiation exposure from abdominal computed tomography (CT) scans in trauma evaluation. The research protocol aims to compare the utility of contrast enhanced abdominal sonography with computerized tomography in the evaluation of children with blunt abdominal trauma. Hemodynamically stable children ages 7-18 who are transferred to Children's Hospital on the trauma service with a CT scan of abdomen & pelvis already performed at the referring institution will be identified by the trauma service as eligible for inclusion. Children who are hemodynamically unstable, known cardiac abnormality, unable to roll over, or unable to assent will be excluded from the study. If the child is enrolled in the study, he/she will have a non contrast ultrasound, followed by a contrast enhanced ultrasound performed in the Radiology Department once he/she is stabilized and evaluation is completed in the Emergency Room. The patient will have vital signs (including blood pressure, heart rate, respiratory rate, oxygen saturation) monitored during the study and 30 minutes after contrast administration.

The ultrasounds will be performed by one of two Attending Radiologists involved in the study. The contrast being used for the study is Optison (GE Healthcare Inc, Princeton, NJ), which is an injectable suspension of Perflutren Protein-Type A Microspheres. This has been used in echocardiography as well as abdominal ultrasonography for evaluation of pediatric abdominal and pelvic solid tumors. After the non contrast ultrasound is performed, the Optison contrast agent will be given via peripheral IV. The contrast enhanced ultrasound will be performed by radiologist. Contrast enhancement only lasts for 3-5 minutes per injection, therefore Optison will be redosed up to 2 additional doses for the completion of the ultrasound. Vital signs will be monitored for 30 minutes after the contrast agent is given and any adverse reactions will be recorded. Adverse reactions to Optison have occurred within this time frame in the literature. Subsequent medical care will be as indicated per the clinical practice guideline. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01763840
Study type Interventional
Source Boston Children’s Hospital
Contact
Status Completed
Phase Phase 1
Start date April 2013
Completion date October 2015

See also
  Status Clinical Trial Phase
Completed NCT05025449 - BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury Phase 4
Completed NCT05538390 - Assessment of Pattern of Abdominal Injury
Completed NCT01938885 - Hepatic Pseudoaneurysms After Trauma N/A
Recruiting NCT05627908 - The PseAn Study - Study Protocol
Recruiting NCT06182488 - Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Emergency Laparotomy N/A
Not yet recruiting NCT06065202 - Personalized Nutrition to Improve Recovery in Trauma Phase 2
Completed NCT02728609 - An Analysis of Cytokine Concentration in Open Abdominal Closure of Trauma Patients N/A
Enrolling by invitation NCT05805852 - Challenges in Management of Abdominal Trauma in Sohag University Hospital A Prospective Study
Not yet recruiting NCT02952976 - Study of Primary Fascial Closure Rate in Patients With Open Abdomen Treated With Abthera Versus Barker Technique Phase 3
Completed NCT03952026 - Impact of Associated Abdominal Injuries on Clinical and Operative Outcome in Pelvic Injuries
Recruiting NCT05127109 - The PASTDUe Nutrition Ecosystem Project (PASTDUe) Phase 4
Not yet recruiting NCT06180668 - Global Outcomes After Laparotomy for Trauma
Recruiting NCT03815370 - A Non-Traumatic Binder for Temporary Abdominal Wall Closure N/A